PPAR active compounds

1. A method for treating a patient suffering from or at risk of a disease or condition for which PPAR modulation provides a therapeutic benefit, comprising

administering to said patient a PPAR modulator having the chemical structure of Formula

I, namely

wherein

U, V, W, X, and Y are independently CR 8 ;

R 1 is —C(O)OR or a carboxylic acid isostere, wherein R is hydrogen, lower alkyl, substituted lower alkyl, aryl, substituted aryl, heteroaryl, of substituted heteroaryl, wherein substituted lower alkyl is a straight chain alkyl, branched alkyl, or cycloalkyl group substituted with 1 to 3 groups or substituents selected from the group consisting of halo, hydroxel, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, acyloxy, aryloxy, heteroaryloxy, amino optionally mono- or di-substituted with alkyl, aryl or heterheteroaryl groups, amidino, urea optionally substituted with alkyl, aryl, heteroaryl or heteroaryl or heterocyclyl groups, aminosulfonyl optionally N-mono- or N,N-di-substituted with alkyl, aryl or heteroaryl groups, alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbonylamino, arylcarbonylamino and heteroarylcarbonylamino;

R 2 is S(O) 2 R 21 ;

R 6 and R 7 are independently hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl, or R 6 and R 7 combine to form a mono-carbocyclic or mono-heterocyclic 5- or 6-membered ring system;

R 8 is hydrogen, halo, optionally substituted lower alkyl, —CH 2 —CR 12 ═CR 13 R 14 , optionally substituted cycloalkyl, optionally substituted monofluoroalkyl, optionally substituted cycloalkyl, —CH 2 —C≡CR 15 , optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, —OR 9 , —SR 9 , —NR 10 R 11 , —C(Z)NR 10 R 11 , —C(Z)R 20 , —S(O) 2 NR 10 R 11 , or —S(O) 2 R 21 ;

R 9 is optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl;

R 10 and R 11 are independently hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl, or R 10 and R 11 combine to form a mono-carbocyclic or mono-heterocyclic 5- or 6-membered ring system;

R 12 , R 13 , R 14 and R 15 are independently optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl;

R 20 is optionally substituted monofluoroalkyl, trifluoromethyl, optionally substituted difluoroalkyl, —CH 2 —CR 12 ═CR 13 R 14 , —CH 2 —C═CR 15 , optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl;

R 21 is optionally substituted lower alkoxy, —CH 2 —CR 12 ═CR 13 R 14 , —CH 2 —C≡CR 15 , optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl;

Z is O or S; and

n=1;

or a pharmaceutically acceptable salt thereof,

wherein said compound is different from 3-(5-methoxy-1-p-toluenesulfonylindol-3-yl)propionic acid and 1-(2,4,6-triisopropylphenylsulfonyl)indole-3-propionic acid, and

wherein the disease or condition is selected from the group consisting of obesity, hyperlipedemia, associated diabetic dyslipidemia, mixed dyslipidemia, hypertriglyceridemia, hypoalphalipoproteinemia, Syndrome X, Type II diabetes mellitus, Type I diabetes, hyperinsulinemia, impaired glucose tolerance insulin resisstance, a diabetic complication of neuropathy, neuropathy, retinopathy or cataracts, cardiovascular disease selected from the group consisting of hypertension, coronary artery disease, heart failure, congestive heart failure, atherosclerosis, and atherosclerosis; eczema, psoriasis, colitis, and regulation of appetite and food intake.

2. The method of claim 1 , wherein said compound is a compound selected from the group consisting of

R 3 , R 4 , R 5 are independently hydrogen, halo, trifluoromethyl, optionally substituted lower alkly, —CH 2 —CR 12 ═CR 13 R 14 , —CH 2 —C≡CR 15 , optionally substituted cycloalkly, optionally substituted heterocycloalkly, optionally substituted aryl, optionally substituted aralkly, optionally substituted heteroaryl, optionally substituted heteroaralkyl, —OR 9 , —SR 9 , —NR 10 R 11 , —C(Z)NR 10 R 11 , —C(Z)R 20 , —S(O)R 2 NR 10 R 11 , or —S(O) 2 R 21 ;

R 24 is hydrogen, halo, optionally substituted alkly, optionally substituted alkoxy, optionally substituted aryloxy, or optionally substituted —O(CH 2 ) p O-aryl, were p is 1-4); and

R 25 is hydrogen, halo, optionally substituted alkly, optionally substituted alkoxy, or optionally substituted aryloxy; or

R 24 and R 25 together form a fused ring with the phenyl.

3. The method of claim 1 , wherein said compound is a compound selected from the group consisting of

3-[1-(4-butoxy-benzenesulfonyl)-5-metoxy-1H-indol-3-yl]-propionic acid methyl etster,

3-[1-(4-butoxy-benzenesulfonyl)-5-metoxy-1H-indol-3-yl]-propionic acid,

3-[5-methoxy-1-(4-trifluoromethoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid methyl etster,

3-[5-methoxy-1-(4-trifluoromethoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid,

3-[5-methoxy-1-(3-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid methyl etster,

3-[5-methoxy-1-(3-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid,

3-[5-methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid methyl etster,

3-[5-methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid,

3-[5-methoxy-1-(3-trifluoromethoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid methyl etster,

3-[5-methoxy-1-(3-trifluoromethoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid,

3-[1-(4-isopropoxy-benzenesulfonyl)-5-methoxy-1H-indol-3-yl]-propionic acid,

3-[1-(3,4-dimethoxy-benzenesulfonyl)5-1H-indol-3-yl]-propionic acid,

3-[1-(4-methoxy-benzenesulfonyl)-5-ethoxy-1H-indol-3-yl]-propionic acid,

3-[1-(3-trifluoromethoxy-benzenesulfonyl)-5-ethoxy-1H-indol-3-yl]-propionic acid,

3-[1-(4-butoxy-benzenesulfonyl)-5-ethoxy-1H-indol-3-yl]-propionic acid,

3-[1-(3-methoxy-benzenesulfonyl)-5-ethoxy-1H-indol-3-yl]-propionic acid, and

3-[1-(3,5-dimethoxy-benzenesulfonyl)-5-methoxy-1H-indol-3-yl]-propionic acid.

4. The method of claim 1 , wherein said disease is selected from the group consisting of hypertension, coronary artery disease, heart failure, congestive heart failure, atherosclerosis, arteriosclerosis.

5. The method of claim 1 , wherein said disease or condition is selected from the group consisting of congestive heart failure, atherosclerosis, arteriosclerosis, obesity, overweight condition, hyperlipidemia, associated diabetic dyslipidemia, mixed dyslipidemia, hypoalphalipoproteinemia, Syndrome X, Type II diabetes mellitus, Type I diabetes, hyperinsulinemia, impaired glucose-tolerance, and insulin resistance.

6. The method of claim 1 , wherein said compound is a compound selected from the group consisting of

3-(1-benzenesulfonyl)-5-isopropoxy-1H-indol-3-yl]-propionic acid,

3-(1-benzenesulfonyl)-5-5-methoxy-1H-indol-3-yl)-propionic acid,

3-[1-(4-chloro-benzenesulfonyl)-5-methoxy-1H-indol-3-yl]-propionic acid methyl ester,

3-[1-(4-chloro-benzenesulfonyl)-5-methoxy-1H-indol-3-yl]-propionic acid,

3-[1(4-cyano-benzenesulfonyl)-5-methoxy-1H-indol-3-yl]-propionic acid methyl ester,

3-[1(4-cyano-benzenesulfonyl)-5-methoxy-1H-indol-3-yl]-propionic acid methyl ester,

3-[1(3,4-dichloro-benzenesulfonyl)-5-methoxy-1H-indol-3-yl]-propionic acid methyl ester,

3-[1(3,4-dichloro-benzenesulfonyl)-5-methoxy-1H-indol-3-yl]-propionic acid,

3-[1(4-fluoro-benzenesulfonyl)-5-methoxy-1H-indol-3-yl]-propionic acid methyl ester,

3-[1(4-fluoro-benzenesulfonyl)-5-methoxy-1H-indol-3-yl]-propionic acid,

3-[1(3-fluoro-benzenesulfonyl)-5-methoxy-1H-indol-3-yl]-propionic acid methyl ester,

3-[1(3-fluoro-benzenesulfonyl)-5-methoxy-1H-indol-3-yl]-propionic acid,

3-[1(3-chloro-benzenesulfonyl)-5-methoxy-1H-indol-3-yl]-propionic acid methyl ester,

3-[1(3-chloro-benzenesulfonyl)-5-methoxy-1H-indol-3-yl]-propionic acid,

3-(1-benzenesulfonyl-5-exthoxy-1H-indol-3-yl)-propionic acid,

3-(1-benzenesulfonyl-1H-indol-3-yl)-propionic acid,

3-(1-benzenesulfonyl-5-methoxy-1H-indol-3-yl)-propionic acid methtyl ester,

(1-benzenesulfonyl-5-methoxy-1H-indol-3-yl)-acetic acid,

3-(1-benzenesulfonyl-5-methoxy-1H-indol-3-yl)-propionic acid,

3-[1-(3,4difluoro-benzenesulfonyl)-5-methoxy-1H-indol-3-yl]-propionic acid,

3-[1-(3-chloro-4-methyl-benzenesulfonyl)-5-methoxy-1H-indol-3-yl]-propionic acid,

3-[1-(3,-fluoro-4-methyl-benzenesulfonyl)-5-methoxy-1H-indol-3-yl]-propionic acid,

3-[1-(3,4-difluoro-benzenesulfonyl)-5-ethoxy-1H-indol-3-yl]-propionic acid, and

3-[1-(3,5-difluoro-benzenesulfonyl)-5-methoxy-1H-indol-3-yl]-propionic acid.

7. The method of claim 1 , wherein said compound is a compound selected from the group consisting of

3-[5-methoxy-1-(4-phenoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid methyl ester,

3-[5-methoxy-1-(4-phenoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid,

3-[5-methoxy-1-(3-phenoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid methyl ester,

3-[5-methoxy-1-(3-phenoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid,

3-[1-(4-phenoxy-benzenesulfonyl)-5-ethoxy-1H-indol-3-yl]-propionic acid,

3-{5-methoxy-1-[4-(pyridin-3-yloxy)-benzenesulfonyl]-1H-indol-3-yl}-propionic acid,

3-{5-methoxy-1-[4-(pyridin-4-yloxy)-benzenesulfonyl]-1H-indol-3-yl}-propionic acid,

3-{5-methoxy-1-[4-(pyridin-4-yloxy)-benzenesulfonyl]-1H-indol-3-yl}-propionic acid,

3-{5-methoxy-1-[4-(pyridin-3-ylmethoxy)-benzenesulfonyl]-1H-indol-3-yl}-propionic acid,

3-{1-[4-(isoquinolin-3-ylaminomethyl)-benzenesulfonyl]-5-methoxy-1H-indol-3-yl}-propionic acid,

3-{5methoxy-1-[4-(quinolin-6-ylaminomethyl)-benzenesulfonyl]-1H-indol-3-yl}-propionic acid,

3-[5-methoxy-1-(4pyrrolo-[2,3-b]pyridin-1-ylmethyl-benzenesulfonyl)-1H-indol-3-yl]propionic acid,

3-[5-methoxy-1-(4-phenoxymethyl-benzenesulfonyl)-1H-indol-3-yl]propionic acid,

3-{5-methoyl-1-[4-(pyridin-3-ylmethoxy)-benzenesulfonyl]-1H-indol-3-yl}-propionic acid,

3-{1-[4-(4-aminomethyl-benzyloxy)-benzenesulfonyl]-5-methoxy-1H-indol-3-yl}-propionic acid,

3-{1-[4-(4-carbamoyl-benzyloxy)-benzenesulfonyl]-5-methoxy-1H-indol-3-yl}-propionic acid.

8. The method of claim 1 , wherein said compound is a compound selected from the group consisting of

3-[1-(4-isopropyl-benzenesulfonyl)-5-methoxy-1H-indol-3-yl]-propionic acid methyl ester,

3-[1-(4-isopropyl-benzenesulfonyl)-5-methoxy-1H-indol-3-yl]-propionic acid,

3-[5-methoxy-1-(4-trifluoromethy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid methyl ester,

3-[5-methoxy-1-(4-trifluoromethy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid,

3-[5-methoxy-1-(toluene3-sulfonyl)-1H-indol-3-yl]-propionic acid methyl ester,

3-[5-methoxy-1-(toluene3-sulfonyl)-1H-indol-3-yl]-propionic acid,

3-[5-methoxy-1-(3-trifluoromethy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid,

3-[1-(4-butyl-benzenesulfonyl)-5-methoxy-1H-indol-3-yl]-propionic acid methyl ester,

3-[1-(4-butyl-benzenesulfonyl)-5-methoxy-1H-indol-3-yl]-propionic acid,

3-[5-methoxy-1-(3trifluoromethyl-benzenesulfonyl)-1H-indol-3-yl]-propionic acid methyl ester,

3-[1-(4-ethyl-benzenesulfonyl)-5-methoxy-1H-indol-3-yl]-propionic acid,

3-[1-(4-ethyl-benzenesulfonyl)-5-ethoxy-1H-indol-3-yl]-propionic acid, and

3-[1-(4-butyl-benzenesulfonyl)-5-ethoxy-1H-indol-3-yl]-propionic acid.

9. The method of claim 1 , wherein said compound is a compound selected from the group consisting of

3-[5-ethyl-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid,

3-(1-benzenesulfonyl-5-bromo-1H-indol-3-yl)-propionic acid,

3-(1-benzenesulfonyl-5-bromo-1H-indol-3-yl)-propionic acid methyl ester,

3-(1-benzenesulfonyl-5-thiophen-3-yl-1H-indol-3-yl)-propionic acid methyl ester,

3-(1-benzenesulfonyl-5-thiophen-3-yl-1H-indol-3-yl)-propionic acid,

3-(1-benzenesulfonyl-5-phenyl-1H-indol-3-yl)-propionic acid methyl ester,

3-(1-benzenesulfonyl-5-phenyl-1H-indol-3-yl)-propionic acid,

3-(1-benzenesulfonyl-5-ethyl-1H-indol-3-yl)-propionic acid,

3-[1-benzenesulfonyl)-5-fluoro-1H-indol-3-yl]-propionic acid,

3-[1-benzenesulfonyl)-5-methyl-1H-indol-3-yl]-propionic acid, and

3-[1-benzenesulfonyl)-5-chloro-1H-indol-3-yl]-propionic acid.